We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Topics Covered
- An overview of CAR-T cell therapy
- Introduction to the mode of action of CAR-T cell therapy
- Differences between CAR-T and TCR-T therapies
- Resistance mechanisms to CAR-T cell therapy
Biography
Sebastian Kobold is Professor of Medicine and Experimental Immuno-oncology at the Medical Faculty of the Ludwig-Maximilians-Universität München in Munich Germany. He is board certified clinical pharmacologist and immunologist. Dr. Kobold is also deputy director of the division of clinical pharmacology at the university hospital of the LMU. The focus of Dr. Kobold´s research work is on developing novel cellular therapy approaches against cancer and deciphering novel resistance mechanisms that need to be overcome for T cell activity.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobold, S. (2021, February 1). CAR-T and TCR-T cellular immunotherapies in oncology [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/YPCI7467.Export Citation (RIS)
Publication History
Financial Disclosures
- Sebastian Kobold (S.K.) has licensed IP to TCR2 Inc, Boston. S.K. has received research support from TCR2 Inc and Arcus Biosciences. S.K. serves on the scientific advisory board of TCR2 Inc and on various scientific advisory boards of Novartis.
Audio Interview
CAR-T and TCR-T cellular immunotherapies in oncology
Published on February 1, 2021
28 min
Other Talks in the Playlist: Research and Clinical Interviews
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Sebastian Kobold, Thank you
very much for taking the time to do this interview with us today,
to discuss the potential of engineered T-cell therapies in the fight against cancer.
Let me jump right in and ask you if you could provide
us with a short summary of the role of
T-cell receptors in immunity and why they
are important tools in the fight against cancer specifically.
Prof. Kobold: Sure, T-cells are among,
or if not the most powerful immune cell that we have in our body,
both for the fight against cancer but also against all sorts of infections.
T-cells do sense their target,
should be it the target cell or target antigen through the T-cell receptor,
which is a very specific structure on the surface,
which is very specific and timeless,
are uniquely specific for
just very defined motives that are found expressed or presented on cell surface.
The reason why they're so powerful is
because they're very specific but also very sensitive,
so meaning that you only need really minute amounts of the target antigen expressed
in the target cell to trigger the T-cell and to make the cell lyse the cancer cell.
As to why it is important for cancer and both for
cancer treatment but also for the understanding of the development of
cancer is that we've realized quite some time ago
that actually T-cells constantly interact with tumor cells.
Thankfully, this actually prevents us from getting cancer
much more frequently in our life than we currently have or that we currently do.